Summary
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Official Title
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs
Keywords
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome, Coronavirus Infections, COVID-19, Hyperaldosteronism, Hemophilia A, Sleep Initiation and Maintenance Disorders, Infectious Skin Diseases, Cardiac Arrhythmias, Hemorrhage, Attention Deficit Disorder with Hyperactivity, COVID-19 related pediatric multisystem inflammatory disease, Mucocutaneous Lymph Node Syndrome, Hemostatic Disorders, Aminocaproic Acid, Amiodarone, Bosentan, Budesonide, Cefdinir, Cefepime, Ceftazidime, Clindamycin, Clobazam, Dexamethasone, Dexmedetomidine, SLI381, Fosfomycin, Furosemide, Gabapentin, Guanfacine, Hydrocortisone, Labetalol, Meropenem, Metformin, Milrinone, Nalbuphine, Nicardipine, Nifedipine, Oseltamivir, Oxycodone, Risperidone, Sertraline, Sevelamer, Spironolactone, Terbutaline, Tranexamic Acid, Voriconazole, Zolpidem, Azithromycin, Lopinavir, Ribavirin, tocilizumab, Interleukin 1 Receptor Antagonist Protein, Aspirin, canakinumab, Colchicine, Interferons, remdesivir, ruxolitinib, sarilumab, Abatacept, Infliximab